Innovative Pharmaceutical Biotech Limited

SEHK:399 Stock Report

Market Cap: HK$373.6m

Innovative Pharmaceutical Biotech Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure9yrs
Board average tenure13.1yrs

Recent management updates

Recent updates

We Believe That Innovative Pharmaceutical Biotech's (HKG:399) Weak Earnings Are A Good Indicator Of Underlying Profitability

Jan 03
We Believe That Innovative Pharmaceutical Biotech's (HKG:399) Weak Earnings Are A Good Indicator Of Underlying Profitability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12
Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05
Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18
Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26
Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

CEO

Innovative Pharmaceutical Biotech has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Rong Tang
Executive Director10.3yrsHK$548.00k0.022%
HK$ 81.2k
Yuan Xing Gao
Executive Director9yrsHK$1.36mno data
Tak Yiu Cheng
Executive director1.5yrsHK$90.00kno data
Yumin Mao
Honorary Chairman & Chief Scientific Adviser4.3yrsno data26.24%
HK$ 98.0m
Hon Yin Poon
Financial Controller & Company Secretary11.7yrsno datano data
Qi Dong
Sales Head of the Groupno datano datano data
Wei Yu
Joint Chairman to the Department of Innovation & Strategic Development and Advisorno datano datano data
Jie Gu
Adviser and Joint Chairman to the Department of Innovation & Strategic Development9.1yrsno datano data
Yi Xie
Chief Executive of United Gane Holdings Limitedno datano datano data
Dong Hui
General Manager of the Group and Director of CJVno datano datano data

9.0yrs

Average Tenure

60yo

Average Age

Experienced Management: 399's management team is seasoned and experienced (9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rong Tang
Executive Director10.3yrsHK$548.00k0.022%
HK$ 81.2k
Yuan Xing Gao
Executive Director9yrsHK$1.36mno data
Tak Yiu Cheng
Executive director1.5yrsHK$90.00kno data
Yumin Mao
Honorary Chairman & Chief Scientific Adviser14.3yrsno data26.24%
HK$ 98.0m
Dong Hui
General Manager of the Group and Director of CJVno datano datano data
Chung Lau
Director of CJVno datano datano data
Weijun Chen
Independent Non-Executive Director15.2yrsHK$80.00kno data
Nian Jiang
Non Executive Chairman14.1yrsHK$60.00kno data
Yanmin Wu
Non-Executive Director13.6yrsHK$60.00kno data
Rongliang Wang
Independent Non-Executive Director13.6yrsHK$60.00kno data
Yan Xiao
Non-Executive Director12.7yrsHK$60.00kno data
Jinzhong Chen
Independent Non-Executive Director3.9yrsHK$60.00kno data

13.1yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 399's board of directors are seasoned and experienced ( 13.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 16:21
End of Day Share Price 2025/01/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innovative Pharmaceutical Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jayaprabha DhavaleVirtua Research Inc.